Naxitamab

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Naxitamab for Relapsed/Refractory Neuroblastoma.

Naxitamab for Relapsed/Refractory Neuroblastoma.

Journal: Journal of pediatric hematology/oncology nursing

Published: February 19, 2026

Concurrent naxitamab and lorlatinib in a patient with refractory high-risk neuroblastoma: a case report.

Concurrent naxitamab and lorlatinib in a patient with refractory high-risk neuroblastoma: a case report.

Journal: Frontiers in oncology

Published: January 17, 2026

Low-Dose Intravenous Ketamine for Primary Pain Control During Naxitamab Anti-GD2 Immunotherapy Treatment.

Low-Dose Intravenous Ketamine for Primary Pain Control During Naxitamab Anti-GD2 Immunotherapy Treatment.

Journal: Pediatric blood & cancer

Published: January 06, 2026

Immunotherapeutic advances in pediatric neuroblastoma: Overcoming resistance through biomarker-guided combinations.

Immunotherapeutic advances in pediatric neuroblastoma: Overcoming resistance through biomarker-guided combinations.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: November 14, 2025

A pharmacological and clinical profile of Naxitamab for the treatment of high-risk neuroblastoma.

A pharmacological and clinical profile of Naxitamab for the treatment of high-risk neuroblastoma.

Journal: Expert review of clinical pharmacology

Published: October 20, 2025

A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remission.

A phase II trial of naxitamab plus stepped-up dosing of GM-CSF for patients with high-risk neuroblastoma in second or later complete remission.

Journal: International journal of cancer

Published: October 03, 2025

Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remission.

Naxitamab with novel scheduling and stepped-up dosing of GM-CSF plus vaccine, but no myeloablative therapy for patients with high-risk neuroblastoma in first complete remission.

Journal: International journal of cancer

Published: September 24, 2025

Naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial.

Naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trial.

Journal: Journal of hematology & oncology

Published: September 22, 2025

The Price of Survival: Global Inequities in Anti-GD2 Immunotherapy for Neuroblastoma.

The Price of Survival: Global Inequities in Anti-GD2 Immunotherapy for Neuroblastoma.

Journal: Pediatric blood & cancer

Published: August 31, 2025

Ganglioside Profiling Uncovers Distinct Patterns in High-Risk Neuroblastoma.

Ganglioside Profiling Uncovers Distinct Patterns in High-Risk Neuroblastoma.

Journal: International journal of molecular sciences

Published: August 01, 2025

Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.

Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison.

Journal: Cancers

Published: July 24, 2025

Affinity Affects the Functional Potency of Anti-GD2 Antibodies by Target-Mediated Drug Disposition.

Affinity Affects the Functional Potency of Anti-GD2 Antibodies by Target-Mediated Drug Disposition.

Journal: Cancers

Published: June 04, 2025

Showing 1-12 of 51

Last Updated: 04/28/2026